CD8A and neoplasm: Importantly, the bibodies were able to enhance ADCC of other tumor specific mAbs with non-engineered or engineered Fc as well as tumor cell killing by CD8+ cytotoxic T cells in combination with T cell engagers beyond the maximum level mediated by FcγRIIIA or CD3 triggering, respectively.